Prospective, multicentre trial evaluating FET-PET in Glioblastoma

The FIG trial is investigating how the addition of FET-PET imaging to standard MRI imaging affects radiation target volume delineation and treatment planning for Glioblastoma, as well as determining the accuracy and management impact of FET-PET in distinguishing pseudoprogression from true tumour progression and / or tumour recurrence.

Primary Sponsor

Trans Tasman Radiation Oncology Group (TROG)

Collaborating Groups

COGNO, ARTnet, ONJCRI

Participating Centres

Accrual Target

210

Current Accrual

Expected Date of Accrual

31 December 2024

Trial Chairperson

Prof Andrew Scott, Olivia Newton-John Cancer Research Institute (ONJCRI) / The Austin Health, VIC, Australia

A/Prof Eng-Siew Koh, Liverpool Hospital, NSW, Australia

Trial Contact

FIG@trog.com.au

Clinical Trial Registration

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Related Post

Dr Anna Lawless, EI SIG Chair 2025
10 December, 2025

Shaping the future: How TROG’s Emerging Investigators group is breaking down barriers for new researchers

SPECIAL INTEREST GROUP IN FOCUS: 10 December 2025 Dr

9 December, 2025

TROG’s inaugural Km’s for Cancer Research brings community together to support our work

LATEST NEWS: 9 December 2025 As we wrap up